DGIdb - DINACICLIB Drug Record

DINACICLIB chembl:CHEMBL2103840 Antineoplastic

Alternate Names:

MK-7965
DINACICLIB
SCH-727965

Drug Info:

Pharmaceutical Developer	Merck
Source Reported Drug Name(s)	Dinaciclib (SCH727965)
Drug Class	Pan-CDK Inhibitor
Drug Class	Kinase Inhibitors

(6 More Sources)

Publications:

Chen Z et al., 2016, Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity., Sci Rep
Schonbrunn E et al., 2013, Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases., J Med Chem
Au-Yeung et al., 2017, Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition., Clin. Cancer Res.
Danilov et al., 2016, Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2., Mol. Cancer Ther.
Hu et al., 2015, Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models., Mol. Cancer Ther.
Baker et al., 2016, The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia., Cancer Res.

DINACICLIB CCNE1

Interaction Score: 4.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27663592

Sources:
ClearityFoundationBiomarkers CIViC
DINACICLIB CDK9

Interaction Score: 1.87

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Direct Interaction yes

Mechanism of Interaction Cyclin-dependent kinase 9 inhibitor

PMIDs:
27378523

Sources:
MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CIViC CancerCommons
DINACICLIB CDK2

Interaction Score: 0.79

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Mechanism of Interaction Cyclin-dependent kinase 2 inhibitor

Direct Interaction yes

PMIDs:
23600925

Sources:
DTC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial
DINACICLIB CDK1

Interaction Score: 0.72

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Mechanism of Interaction Cyclin-dependent kinase 1 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial
DINACICLIB CDK5

Interaction Score: 0.65

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 5 inhibitor

Direct Interaction yes

Reported Cancer Type Melanoma

PMIDs:
None found

Sources:
MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons
DINACICLIB NRAS

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

Approval Status Preclinical

PMIDs:
26627013

Sources:
JAX-CKB
DINACICLIB KMT2A

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

Approval Status Preclinical

PMIDs:
26627013

Sources:
JAX-CKB
DINACICLIB MYC

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
DINACICLIB KRAS

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Dinaciclib + MK2206

Indication/Tumor Type pancreatic ductal adenocarcinoma

Response Type sensitive

PMIDs:
27550941 25931518

Sources:
JAX-CKB

MyCancerGenome: DINACICLIB
- Version: 20-Jun-2017
Alternate Names:

SCH727965 Development Name

DINACICLIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
CancerCommons: SCH727965
- Version: 25-July-2013
Alternate Names:

Dinaciclib PubChem Drug Name

46926350 PubChem Drug ID

Dinaciclib Drug Trade Name

Drug Info:

Drug Class Pan-CDK Inhibitor

Source Reported Drug Name(s) Dinaciclib (SCH727965)

Pharmaceutical Developer Merck

Publications:
DTC: DINACICLIB
- Version: 02-September-2020
Alternate Names:

CHEMBL2103840 ChEMBL Drug ID

Drug Info:

Publications:

Schonbrunn E et al., 2013, Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases., J Med Chem

JAX-CKB: Dinaciclib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Baker et al., 2016, The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia., Cancer Res.

Danilov et al., 2016, Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2., Mol. Cancer Ther.

Hu et al., 2015, Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models., Mol. Cancer Ther.

CIViC: DINACICLIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Au-Yeung et al., 2017, Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition., Clin. Cancer Res.

Chen Z et al., 2016, Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity., Sci Rep

ChemblDrugs: chembl:CHEMBL2103840
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: DINACICLIB
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: DINACICLIB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL2103840
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: DINACICLIB
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:

Reported Cancer Type	Melanoma
Direct Interaction	yes
Mechanism of Interaction	Cyclin-dependent kinase 9 inhibitor

Mechanism of Interaction	Cyclin-dependent kinase 5 inhibitor
Direct Interaction	yes
Reported Cancer Type	Melanoma

Indication/Tumor Type	acute myeloid leukemia
Response Type	sensitive
Approval Status	Preclinical

combination therapy	Dinaciclib + MK2206
Indication/Tumor Type	pancreatic ductal adenocarcinoma
Response Type	sensitive

Dinaciclib	PubChem Drug Name
46926350	PubChem Drug ID
Dinaciclib	Drug Trade Name

DINACICLIB Drug Record

DINACICLIB chembl:CHEMBL2103840 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27663592

Sources: ClearityFoundationBiomarkers CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Reported Cancer Type Melanoma Direct Interaction yes Mechanism of Interaction Cyclin-dependent kinase 9 inhibitor

PMIDs: 27378523

Sources: MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CIViC CancerCommons

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Reported Cancer Type Melanoma Mechanism of Interaction Cyclin-dependent kinase 2 inhibitor Direct Interaction yes

PMIDs: 23600925

Sources: DTC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Reported Cancer Type Melanoma Mechanism of Interaction Cyclin-dependent kinase 1 inhibitor Direct Interaction yes

PMIDs: None found

Sources: MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cyclin-dependent kinase 5 inhibitor Direct Interaction yes Reported Cancer Type Melanoma

PMIDs: None found

Sources: MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type acute myeloid leukemia Response Type sensitive Approval Status Preclinical

PMIDs: 26627013

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type acute myeloid leukemia Response Type sensitive Approval Status Preclinical

PMIDs: 26627013

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Dinaciclib + MK2206 Indication/Tumor Type pancreatic ductal adenocarcinoma Response Type sensitive

PMIDs: 27550941 25931518

Sources: JAX-CKB

MyCancerGenome: DINACICLIB

Alternate Names: SCH727965 Development Name DINACICLIB Generic Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

CancerCommons: SCH727965

Alternate Names: Dinaciclib PubChem Drug Name 46926350 PubChem Drug ID Dinaciclib Drug Trade Name

Drug Info: Drug Class Pan-CDK Inhibitor Source Reported Drug Name(s) Dinaciclib (SCH727965) Pharmaceutical Developer Merck

Publications:

DTC: DINACICLIB

Alternate Names: CHEMBL2103840 ChEMBL Drug ID

Drug Info:

Publications: Schonbrunn E et al., 2013, Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases., J Med Chem

JAX-CKB: Dinaciclib

Alternate Names:

Drug Info:

CIViC: DINACICLIB

Alternate Names:

Drug Info:

ChemblDrugs: chembl:CHEMBL2103840

Alternate Names:

Drug Info:

Publications:

ClearityFoundationBiomarkers: DINACICLIB

Alternate Names:

Drug Info:

Publications:

ClearityFoundationClinicalTrial: DINACICLIB

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL2103840

Alternate Names:

Drug Info:

Publications:

MyCancerGenomeClinicalTrial: DINACICLIB

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
27663592

Sources:
ClearityFoundationBiomarkers CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Direct Interaction yes

Mechanism of Interaction Cyclin-dependent kinase 9 inhibitor

PMIDs:
27378523

Sources:
MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CIViC CancerCommons

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Mechanism of Interaction Cyclin-dependent kinase 2 inhibitor

Direct Interaction yes

PMIDs:
23600925

Sources:
DTC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Mechanism of Interaction Cyclin-dependent kinase 1 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 5 inhibitor

Direct Interaction yes

Reported Cancer Type Melanoma

PMIDs:
None found

Sources:
MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

Approval Status Preclinical

PMIDs:
26627013

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

Approval Status Preclinical

PMIDs:
26627013

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Dinaciclib + MK2206

Indication/Tumor Type pancreatic ductal adenocarcinoma

Response Type sensitive

PMIDs:
27550941 25931518

Sources:
JAX-CKB

Alternate Names:

SCH727965 Development Name

DINACICLIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Alternate Names:

Dinaciclib PubChem Drug Name

46926350 PubChem Drug ID

Dinaciclib Drug Trade Name

Drug Info:

Drug Class Pan-CDK Inhibitor

Source Reported Drug Name(s) Dinaciclib (SCH727965)

Pharmaceutical Developer Merck

Alternate Names:

CHEMBL2103840 ChEMBL Drug ID

Publications:

Schonbrunn E et al., 2013, Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases., J Med Chem